What Management Said
Read the full Q2 2026 transcript ↗We delivered a solid second quarter with better-than-expected revenue, earnings, and cash flow. We were particularly pleased to see an acceleration in core growth versus the first quarter, driven by good commercial execution, recent innovation, and recovery in our end market. While customer project timing impacted bioprocessing revenue, underlying order trends remained robust. Improved growth across our portfolio, paired with benefits from our recent productivity initiatives, helped drive high single-digit earnings growth.
This strong execution and the earlier-than-expected close of Masimo enables us to again raise our full year adjusted EPS guidance. The quarter illustrates the benefit of our balanced end market and geographic diversification while reinforcing our outlook for accelerating revenue and earnings growth in the second half and beyond. Demand from large pharma and biopharma customers remained healthy, while improved biotech funding supported improved funnel and order activity. Our capital deployment flywheel is active, supported by significant balance sheet optionality.
The Danaher Business System and our team are powerful differentiators, helping us drive both growth and productivity. Core growth, excluding respiratory testing revenue, which highlights improvements in the underlying business trends that I mentioned a moment ago, was up 4.5%, 150 basis point acceleration from the first quarter. We were encouraged to see growth accelerate with improving trends across our end markets and recent innovations further driving growth across our businesses. Geographically, core revenues in developed markets declined slightly as both North America and Western Europe were impacted by shipment timing in biotechnology and lower respiratory revenue year-over-year.
What went well
- Danaher delivered a solid second quarter with better-than-expected revenue, earnings and cash flow, and core growth accelerated versus the first quarter; core revenue excluding respiratory testing rose 4.5%, a 150-basis-point acceleration from Q1.
- The Life Sciences segment delivered its strongest quarter in several years with 5.5% core growth, led by ~10% growth at Pall's applied filtration business (microelectronics/semiconductor strength) and Abcam's best quarter since acquisition.
- GAAP net earnings were $870 million, or $1.23 per diluted share, up 60% year over year, and non-GAAP adjusted EPS grew about 8% to $1.94, aided by productivity initiatives.
- The company closed its Masimo acquisition in early June, ahead of schedule; Masimo delivered high-single-digit first-half growth, is immediately accretive, and already secured an FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection solution.
- Free cash flow was $1.3 billion in the quarter and $2.4 billion in the first half, a 124% free-cash-flow-to-net-income conversion, while Danaher also announced the pending ~$250 million-revenue StatLab acquisition (85%+ recurring) for Leica Biosystems and repurchased 5 million shares for ~$900 million.
- The early Masimo close and strong execution enabled Danaher to again raise full-year adjusted EPS guidance to $8.45-$8.60, implying nearly 10% EPS growth at the midpoint.
What went wrong
- Bioprocessing consumables revenue came in below expectations as a few large chromatography-resin shipments (~$50-60 million in Q2) were pushed out at customers' request due to production-schedule and site-readiness changes; a bit more than $100 million shifted out of Q2/Q3 into 2027.
- As a result, the full-year bioprocessing growth outlook was reduced from high-single-digit to mid-single-digit (a couple hundred basis points of impact), with the pushed-out revenue not assumed to return in Q4.
- Adjusted operating profit margin declined 20 basis points to 27.1% as lower year-over-year respiratory testing revenue more than offset higher non-respiratory volume and cost discipline.
- Core revenue in developed markets declined slightly as North America and Western Europe were hit by biotechnology shipment timing and lower respiratory revenue; academic demand remained below normal levels.
- Respiratory testing was about a 150-basis-point headwind in Q2 and is expected to be a ~250-basis-point headwind in Q3, and management anchored full-year core growth to the low end of its 3%-4% range.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Adjusted diluted EPS | FY2026 | Raised to $8.45-$8.60 (~10% growth at the midpoint; ~$0.07-$0.08 from the early Masimo close) |
| Core revenue growth | FY2026 | 3%-4%, anchored to the low end for modeling (better Life Sciences offset by more conservative bioprocessing) |
| Core growth ex-respiratory | Q3 2026 | ~5% (slight improvement off Q2's 4.5%), with a ~250 bps respiratory headwind |
| Core revenue growth | Q4 2026 | Mid-single-digit as respiratory headwinds essentially go away year over year |
| Bioprocessing growth | FY2026 | Mid-single-digit (~5%) after >$100M of resin shipments shifted to 2027; exiting Q4 mid-to-high single digit |
| Respiratory revenue | FY2026 | ~$1.6 billion or a touch below |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Total sales | +5.5% to $6.3B | Core revenue up 3% (4.5% excluding respiratory) plus contribution from acquisitions; core growth accelerated 150 bps versus Q1. |
| Biotechnology core revenue | +2.5% | Bioprocessing grew low single digits with equipment returning to growth, but consumables were held back by pushed-out resin shipments despite mid-teens order growth. |
| Life Sciences core revenue | +5.5% | Pall applied filtration up ~10% on microelectronics; instruments up mid-single digits; Abcam and IDT accelerating on improving biotech funding and academic stabilization. |
| Diagnostics core revenue | +2% (+5% ex-respiratory) | Mid-single-digit underlying growth from DxI 9000, Cepheid menu expansion and easing China VBP headwinds, offset by lower respiratory testing. |
| Adjusted operating margin | -20 bps to 27.1% | Lower respiratory revenue more than offset higher non-respiratory volume and disciplined cost management; gross margin 57.6%. |
| Adjusted diluted EPS | +8% to $1.94 | Improved growth across the portfolio plus productivity initiatives; GAAP EPS $1.23, up 60%. |
| Free cash flow | $1.3B in quarter / $2.4B H1 | 124% year-to-date free-cash-flow-to-net-income conversion, underscoring earnings quality. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing recovery and CapEx cycle | Improving order trends post-destocking | Equipment revenue returned to growth after several quarters of order strength; management sees the early innings of a multi-year capacity/reshoring CapEx cycle, with greenfield quoting that takes 2-3 years to convert, and reaffirmed the high-single-digit long-term bioprocessing outlook. | — |
| Capital deployment flywheel | Active M&A pipeline | Masimo closed early and is immediately accretive; StatLab (~$250M revenue, 85%+ recurring) pending for Leica Biosystems; ~$900M deployed on buybacks, with significant balance-sheet optionality remaining. | — |
| End-market stabilization | Softness across academic/biotech | Large pharma/biopharma healthy, biotech funding improving and starting to convert to orders, academic stabilizing but still below normal (<5% of revenue), and China diagnostics improving as VBP headwinds ease. | — |
| Innovation and AI | Ongoing product launches | New launches (Cytiva Biacore 8S, SCIEX novus V55, Beckman Alzheimer's p-tau217 assays) plus early 'green shoots' of AI-driven demand for automation and autonomous/lab-in-a-loop applications, notably at Beckman. | — |
| Respiratory normalization | Elevated respiratory comparisons | Respiratory a ~150 bps drag in Q2 and ~250 bps in Q3, then essentially neutral year over year in Q4, driving the expected second-half core-growth acceleration; FY respiratory ~$1.6 billion. | — |
Q&A Summary
Michael Ryskin (Bank of America) pressed on why the pushed-out bioprocessing revenue is not recovering in Q3/Q4 and whether it is a multi-quarter rebase.
Blair said a few large chromatography-resin shipments ($10-30M each) moved out at customers' request for production/site-readiness reasons with no change in underlying trends; Gugino sized it at ~500 bps (~$50-60M) in Q2 and >$100M for the full year shifting to 2027, not assumed to return in Q4.
Ryskin followed up on whether business visibility has changed given the size of the swing.
Blair said the delay is concentrated in a few commercial customers with no broad-based demand change; post-pandemic visibility processes are functioning, market inventory is lower than prior years, scripts are strong, and shorter lead times allow safety stocks to fall.
Tycho Peterson (Jefferies) asked about confidence in bioprocessing equipment into the back half and 2027.
Blair said returning equipment revenue signals reshoring/brownfield expansion reading through after four quarters of order growth, and that Danaher is in the early innings of a multi-year CapEx cycle, with greenfield investments taking two to three years to convert.
Dan Leonard (RBC) asked whether there is a common thread among the customers that delayed shipments.
Blair said the only commonality is resin shipments for large-batch commercial molecules across a couple of geographies and different molecules, not a single molecule or customer, reflecting the complexity of building new plants.
Scott Davis (Melius) asked for an early read on Masimo and the shape of an academic/government recovery.
Blair confirmed Masimo grew high single digits in the quarter with potential upside, and said academic funding depends on government policy so Danaher expects continued stability rather than a called inflection, noting academia is less than 5% of revenue.
Vijay Kumar (Evercore ISI) asked why the EPS raise (~$0.08) was smaller than the combined beat and Masimo contribution.
Gugino said guidance went to $8.45-$8.60 including ~$0.07-$0.08 from the early Masimo close (originally a 2027 item), with partial offsets from mix/FX and a deliberate second-half hedge, implying nearly 10% EPS growth.
Jack Meehan (Operon) asked about Pall's ~10% growth composition and why the Life Sciences segment softens to 3%-4% in Q3.
Gugino said microelectronics led (above 10%) with good energy/aerospace growth and some share gains, and that the sequential moderation reflects some Pall project timing rather than any change in underlying trends.
Patrick Donnelly (Citi) asked whether the resin push-out is leaking into single-use consumables and about confidence the Life Sciences market is turning.
Blair said it is limited to a few very large customers and resins, with strong upstream/single-use growth, and that the encouraging 5.5% Life Sciences result reflected broad end-market improvement, share gains at Abcam, new products, and early AI-driven automation demand.
More on Danaher Corp /De/
Reported 2026-07-21 · figures from the Danaher Corp /De/ Q2 2026 earnings call.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.